Evidence map›Paper›PMID 38399410›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation.

Reem A Qannita, Ayah I Alalami, Amani A Harb, Shereen M Aleidi, Jalal Taneera, Eman Abu-Gharbieh, Waseem El-Huneidi, Mohamed A Saleh, Karem H Alzoubi, Mohammad H Semreen and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 2 pooled it
25.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Interaction of HIF-1a with various cell death pathways in tumor immune microenvironment (TIME).Apoptosis : an international journal on programmed cell death · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Genomic alterations and their correlation with metabolic-related genes in lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Reem A QannitaResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Ayah I AlalamiResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Amani A HarbDepartment of Basic Sciences, Faculty of Arts and Sciences, Al-Ahliyya Amman University, Amman 19111, Jordan.
Shereen M AleidiSchool of Pharmacy, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0001-9222-464X
Jalal TaneeraResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-3341-1063
Eman Abu-GharbiehResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-5972-0681
Waseem El-HuneidiResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-1580-2589
Mohamed A SalehResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-6405-6033
Karem H AlzoubiResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.
Mohammad H SemreenResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-0169-7538
Mohammad HudaibSchool of Pharmacy, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0003-1400-462X
Yasser BustanjiResearch Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0003-1315-0609
University of Sharjah · AEUniversity of Jordan · JOAl-Ahliyya Amman University · JOMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia-inducible factor-1 (HIF-1) is a key regulator for balancing oxygen in the cells. It is a transcription factor that regulates the expression of target genes involved in oxygen homeostasis in response to hypoxia. Recently, research has demonstrated the multiple roles of HIF-1 in the pathophysiology of various diseases, including cancer. It is a crucial mediator of the hypoxic response and regulator of oxygen metabolism, thus contributing to tumor development and progression. Studies showed that the expression of the HIF-1α subunit is significantly upregulated in cancer cells and promotes tumor survival by multiple mechanisms. In addition, HIF-1 has potential contributing roles in cancer progression, including cell division, survival, proliferation, angiogenesis, and metastasis. Moreover, HIF-1 has a role in regulating cellular metabolic pathways, particularly the anaerobic metabolism of glucose. Given its significant and potential roles in cancer development and progression, it has been an intriguing therapeutic target for cancer research. Several compounds targeting HIF-1-associated processes are now being used to treat different types of cancer. This review outlines emerging therapeutic strategies that target HIF-1 as well as the relevance and regulation of the HIF-1 pathways in cancer. Moreover, it addresses the employment of nanotechnology in developing these promising strategies.

Indexed as

cancerHIF-1 inhibitorsHIF-1αhypoxiahypoxia-inducible factor-1metabolism reprogrammingnanotechnology

Identifiers

PMID38399410
PMCPMC10892333
OpenAlexW4391449910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.